Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic OTC Lamisil approved

This article was originally published in The Tan Sheet

Executive Summary

FDA on July 2 approves Taro Pharmaceutical U.S.A's application for a generic version of Novartis' OTC athlete's foot cream Lamisil AT (terbinafine hydrochloride, 1 percent). Taro's product will be the first generic Lamisil cream on the market, according to FDA. The firm was granted tentative approval in March 2006 (1"The Tan Sheet" March, 27, 2006, p. 11). Novartis recently introduced a gel form, Lamisil AT Gel Advanced, which "cures most athlete's foot with 1/2 the applications of any other product," according to the product Web site. FDA also approved the first generic versions of Rx Lamisil tablets as the remaining patent or exclusivity for the drug expired June 30...

You may also be interested in...



Taro Granted Tentative Approval For First Lamisil Cream Equivalent

Taro Pharmaceuticals has received what appears to be the first tentative approval in the U.S. for a generic version of Novartis' OTC antifungal cream Lamisil, the Israeli firm announced March 23

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100690

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel